Academic Publications

Academic peer reviewed journal articles which include Cancer Trials Ireland Members as co-authors

2018 Publications

Study Number Publication Details


Colleoni, M., W. Luo, P. Karlsson, J. Chirgwin, S. Aebi, G. Jerusalem, P. Neven, E. Hitre, M. P. Graas, E. Simoncini, C. Kamby, A. Thompson, S. Loibl, J. Gavilá, K. Kuroi, C. Marth, B. Müller, S. O’Reilly, V. Di Lauro, A. Gombos, T. Ruhstaller, H. Burstein, K. Ribi, J. Bernhard, G. Viale, R. Maibach, M. Rabaglio-Poretti, R. D. Gelber, A. S. Coates, A. Di Leo, M. M. Regan, A. Goldhirsch and S. Investigators (2018). “Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.” Lancet Oncol 19(1): 127-138.
10-12 King, M. T., M. R. Stockler, R. L. O’Connell, L. Buizen, F. Joly, A. Lanceley, F. Hilpert, A. Okamoto, E. Aotani, J. Bryce, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, J. Sehouli, A. Feeney, D. Berton-Rigaud, D. S. J. Costa, M. L. Friedlander and G. S. B. group (2018). “Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.” Qual Life Res 27(1): 59-74.


Roncolato, F. T., D. Berton-Rigaud, R. O’Connell, A. Lanceley, J. Sehouli, L. Buizen, A. Okamoto, E. Aotani, D. Lorusso, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. Berek, F. Hilpert, J. A. Ledermann, M. C. Kaminsky, M. R. Stockler, M. T. King and M. Friedlander (2018). “Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).” Gynecol Oncol 148(1): 36-41.


Sonnenblick, A., R. Salgado, S. Brohée, T. Zahavi, T. Peretz, G. Van den Eynden, G. Rouas, A. Salmon, P. A. Francis, A. Di Leo, J. P. A. Crown, G. Viale, L. Daly, B. Javdan, S. Fujisawa, E. De Azambuja, A. Lieveke, M. J. Piccart, J. F. Bromberg and C. Sotiriou (2018). “p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.” Int J Oncol 52(2): 424-432.

2017 Publications

Study Number Publication Details
14-13 Brahmer, J. R., D. Rodríguez-Abreu, A. G. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, J. Zhang, G. M. Lubiniecki, A. C. Deitz, R. Rangwala and M. Reck (2017). “Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.Lancet Oncol 18(12): 1600-1609.
97-01, 02-01, 05-04, 06-15, 06-16, 08-17 Cagney, D. N., M. Dunne, C. O’Shea, M. Finn, E. Noone, M. Sheehan, L. McDonagh, L. O’Sullivan, P. Thirion and J. Armstrong (2017). “Heterogeneity in high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation therapy.” BMC Urol 17(1): 60.


Earl, H. M., L. Hiller, H. C. Howard, J. A. Dunn, J. Young, S. J. Bowden, M. McDermaid, A. K. Waterhouse, G. Wilson, R. Agrawal, S. O’Reilly, A. Bowman, D. M. Ritchie, A. Goodman, T. Hickish, K. McAdam, D. Cameron, D. Dodwell, D. W. Rea, C. Caldas, E. Provenzano, J. E. Abraham, P. Canney, J. P. Crown, M. J. Kennedy, R. Coleman, R. C. Leonard, J. A. Carmichael, A. M. Wardley, C. J. Poole and t. t. collaborators (2017). “Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.” Lancet Oncol 18(6): 755-769.

Karam, A., J. A. Ledermann, J. W. Kim, J. Sehouli, K. Lu, C. Gourley, N. Katsumata, R. A. Burger, B. H. Nam, M. Bacon, C. Ng, J. Pfisterer, R. L. M. Bekkers, A. Casado Herráez, A. Redondo, H. Fujiwara, N. Gleeson, O. Rosengarten, G. Scambia, J. Zhu, A. Okamoto, G. Stuart, K. Ochiai and p. o. t. t. O. C. C. Conference (2017). “Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.Ann Oncol 28(4): 711-717.


Medipally, D. K., A. Maguire, J. Bryant, J. Armstrong, M. Dunne, M. Finn, F. M. Lyng and A. D. Meade (2017). “Development of a high throughput (HT) Raman spectroscopy method for rapid screening of liquid blood plasma from prostate cancer patients.Analyst 142(8): 1216-1226.


Moran, B., S. Das, D. Smeets, G. Peutman, R. Klinger, B. Fender, K. Connor, M. Ebert, T. Gaiser, J. H. Prehn, O. Bacon, E. Kay, B. Hennessy, V. Murphy, B. Ylstra, D. Lambrechts, A. T. Byrne, W. M. Gallagher and D. P. O’Connor (2017). “Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.” Oncotarget 8(29): 48126-48137.


Motzer, R. J., N. B. Haas, F. Donskov, M. Gross-Goupil, S. Varlamov, E. Kopyltsov, J. L. Lee, B. Melichar, B. I. Rini, T. K. Choueiri, M. Zemanova, L. A. Wood, M. N. Reaume, A. Stenzl, S. Chowdhury, H. Y. Lim, R. McDermott, A. Michael, W. Bao, M. J. Carrasco-Alfonso, P. Aimone, M. Voi, C. Doehn, P. Russo, C. N. Sternberg and P. investigators (2017). “Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.” J Clin Oncol 35(35): 3916-3923.


Overman, M. J., R. McDermott, J. L. Leach, S. Lonardi, H. J. Lenz, M. A. Morse, J. Desai, A. Hill, M. Axelson, R. A. Moss, M. V. Goldberg, Z. A. Cao, J. M. Ledeine, G. A. Maglinte, S. Kopetz and T. André (2017). “Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.” Lancet Oncol 18(9): 1182-1191.


Peters, S., R. A. Stahel, U. Dafni, S. Ponce Aix, B. Massuti, O. Gautschi, L. Coate, A. Lopez Martin, R. van Heemst, T. Berghmans, P. Meldgaard, M. Cobo Dols, J. Garde Noguera, A. Curioni-Fontecedro, D. Rauch, M. T. Mark, S. Cuffe, B. Biesma, A. M. van Henten, O. Juan Vidal, R. Palmero Sanchez, J. C. Villa Guzman, R. Collado Martin, S. Peralta, A. Insa, Y. Summers, I. Lang, A. Horgan, F. Ciardiello, S. de Hosson, R. Pieterman, H. J. Groen, P. M. van den Berg, C. C. Zielinski, Y. Chittazhathu Kurian Kuruvilla, A. Gasca-Ruchti, M. Kassapian, S. Novello, V. Torri, Z. Tsourti, V. Gregorc, E. F. Smit and E. M.-l. C. Group (2017). “Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.” J Thorac Oncol 12(4): 752-762.


Pinter, T., Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O’Reilly, T. Salek, M. Reiner, P. K. Morrow, M. R. Choi, S. Whittaker and C. Blanke (2016). “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).” Clin Colorectal Cancer 16(2): 103-114.e103.


Reynolds, J. V., S. R. Preston, B. O’Neill, L. Baeksgaard, S. M. Griffin, C. Mariette, S. Cuffe, M. Cunningham, T. Crosby, I. Parker, K. Hofland, G. Hanna, L. B. Svendsen, C. L. Donohoe, C. Muldoon, D. O’Toole, C. Johnson, N. Ravi, G. Jones, A. K. Corkhill, M. Illsley, J. Mellor, K. Lee, M. Dib, V. Marchesin, M. Cunnane, K. Scott, P. Lawner, S. Warren, S. O’Reilly, G. O’Dowd, G. Leonard, B. Hennessy and R. M. Dermott (2017). “ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS).” BMC Cancer 17(1): 401.


Roncolato, F. T., F. Joly, R. O’Connell, A. Lanceley, F. Hilpert, L. Buizen, A. Okamoto, E. Aotani, S. Pignata, P. Donnellan, A. Oza, E. Avall-Lundqvist, J. S. Berek, F. Heitz, A. Feeney, D. Berton-Rigaud, M. R. Stockler, M. King, M. Friedlander and G. S. B. group (2017). “Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.” Oncologist 22(9): 1117-1124.


Rosell, R., U. Dafni, E. Felip, A. Curioni-Fontecedro, O. Gautschi, S. Peters, B. Massutí, R. Palmero, S. P. Aix, E. Carcereny, M. Früh, M. Pless, S. Popat, A. Kotsakis, S. Cuffe, P. Bidoli, A. Favaretto, P. Froesch, N. Reguart, J. Puente, L. Coate, F. Barlesi, D. Rauch, M. Thomas, C. Camps, J. Gómez-Codina, M. Majem, R. Porta, R. Shah, E. Hanrahan, R. Kammler, B. Ruepp, M. Rabaglio, M. Kassapian, N. Karachaliou, R. Tam, D. S. Shames, M. A. Molina-Vila, R. A. Stahel and B. c. group (2017). “Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.” Lancet Respir Med 5(5): 435-444.


Sheill, G., L. Brady, E. Guinan, B. Hayes, O. Casey, J. Greene, T. Vlajnic, F. Cahill, M. Van Hemelrijck, N. Peat, S. Rudman, J. Hussey, M. Cunningham, L. Grogan, T. Lynch, R. P. Manecksha, J. McCaffrey, L. Mucci, O. Sheils, J. O’Leary, D. M. O’Donnell, R. McDermott and S. Finn (2017). “The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial.” Trials 18(1): 456.
07-02 Sonnenblick, A., D. Agbor-Tarh, I. Bradbury, S. Di Cosimo, H. A. Azim, D. Fumagalli, S. Sarp, A. C. Wolff, M. Andersson, J. Kroep, T. Cufer, S. D. Simon, P. Salman, M. Toi, L. Harris, J. Gralow, M. Keane, A. Moreno-Aspitia, M. Piccart-Gebhart and E. de Azambuja (2017). “Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.” J Clin Oncol 35(13): 1421-1429.
13-02 Sznol, M., P. F. Ferrucci, D. Hogg, M. B. Atkins, P. Wolter, M. Guidoboni, C. Lebbé, J. M. Kirkwood, J. Schachter, G. A. Daniels, J. Hassel, J. Cebon, W. Gerritsen, V. Atkinson, L. Thomas, J. McCaffrey, D. Power, D. Walker, R. Bhore, J. Jiang, F. S. Hodi and J. D. Wolchok (2017). “Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.” J Clin Oncol: JCO2016721167.


Toomey, S., A. J. Eustace, J. Fay, K. M. Sheehan, A. Carr, M. Milewska, S. F. Madden, A. Teiserskiene, E. W. Kay, N. O’Donovan, W. Gallagher, L. Grogan, O. Breathnach, J. Walshe, C. Kelly, B. Moulton, M. J. Kennedy, G. Gullo, A. D. Hill, C. Power, D. Duke, N. Hambly, J. Crown and B. T. Hennessy (2017). “Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.” Breast Cancer Res 19(1): 87.


Wakelee, H. A., S. E. Dahlberg, S. M. Keller, W. J. Tester, D. R. Gandara, S. L. Graziano, A. A. Adjei, N. B. Leighl, S. C. Aisner, J. M. Rothman, J. D. Patel, M. D. Sborov, S. R. McDermott, R. Perez-Soler, A. M. Traynor, C. Butts, T. Evans, A. Shafqat, A. E. Chapman, S. S. Kasbari, L. Horn, S. S. Ramalingam, J. H. Schiller and ECOG-ACRIN (2017). “Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol 18(12): 1610-1623.


Xie, W., M. M. Regan, M. Buyse, S. Halabi, P. W. Kantoff, O. Sartor, H. Soule, N. W. Clarke, L. Collette, J. J. Dignam, K. Fizazi, W. R. Paruleker, H. M. Sandler, M. R. Sydes, B. Tombal, S. G. Williams, C. J. Sweeney and I. W. Group (2017). “Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.J Clin Oncol 35(27): 3097-3104.

* Cancer Trials Ireland author listed in supplementary materials

2016 Publications

Study Number Publication Details
12-16 Betge, J., A. Barat, V. Murphy, T. Hielscher, N. C. Van Grieken, S. Belle, T. Zhan, N. Härtel, M. Kripp, O. Bacon, M. Cordes, E. W. Kay, H. M. Verheul, M. Neerincx, B. Hennessy, R. D. Hofheinz, T. Gaiser, B. Ylstra, J. H. Prehn, D. Lambrechts, A. T. Byrne, M. P. Ebert and N. Schulte (2016). “Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.” Digestion 94(3): 129-137.
02-04 Bolla, M., P. Maingon, C. Carrie, S. Villa, P. Kitsios, P. M. Poortmans, S. Sundar, E. M. van der Steen-Banasik, J. Armstrong, J. F. Bosset, F. G. Herrera, B. Pieters, A. Slot, A. Bahl, R. Ben-Yosef, D. Boehmer, C. Scrase, L. Renard, E. Shash, C. Coens, A. C. van den Bergh and L. Collette (2016). “Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.” J Clin Oncol 34(15): 1748-1756.




Dearnaley, D., I. Syndikus, H. Mossop, V. Khoo, A. Birtle, D. Bloomfield, J. Graham, P. Kirkbride, J. Logue, Z. Malik, J. Money-Kyrle, J. M. O’Sullivan, M. Panades, C. Parker, H. Patterson, C. Scrase, J. Staffurth, A. Stockdale, J. Tremlett, M. Bidmead, H. Mayles, O. Naismith, C. South, A. Gao, C. Cruickshank, S. Hassan, J. Pugh, C. Griffin, E. Hall and C. H. Investigators (2016). “Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.” Lancet Oncol 17(8): 1047-1060.


Finn, R. S., J. P. Crown, J. Ettl, M. Schmidt, I. M. Bondarenko, I. Lang, T. Pinter, K. Boer, R. Patel, S. Randolph, S. T. Kim, X. Huang, P. Schnell, S. Nadanaciva, C. H. Bartlett and D. J. Slamon (2016). “Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.Breast Cancer Res 18(1): 67.
12-43 Finn, R. S., M. Martin, H. S. Rugo, S. Jones, S. A. Im, K. Gelmon, N. Harbeck, O. N. Lipatov, J. M. Walshe, S. Moulder, E. Gauthier, D. R. Lu, S. Randolph, V. Dieras and D. J. Slamon (2016). “Palbociclib and Letrozole in Advanced Breast Cancer.” N Engl J Med 375(20): 1925-1936.
05-09 Forbes, J. F., I. Sestak, A. Howell, B. Bonanni, N. Bundred, C. Levy, G. von Minckwitz, W. Eiermann, P. Neven, M. Stierer, C. Holcombe, R. E. Coleman, L. Jones, I. Ellis, J. Cuzick and I.-I. investigators (2016). “Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.” Lancet 387(10021): 866-873.
09-03 Harter, P., T. Johnson, D. Berton-Rigaud, S. Y. Park, M. Friedlander, J. M. Del Campo, M. Shimada, F. Forget, M. R. Mirza, N. Colombo, C. Zamagni, J. K. Chan, M. Imhof, T. J. Herzog, D. O’Donnell, F. Heitz, K. King, S. Stinnett, C. Barrett, M. Jobanputra, C. F. Xu and A. du Bois (2016). “BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.” Gynecol Oncol 140(3): 443-449.
01-04 Press, M. F., G. Sauter, M. Buyse, H. Fourmanoir, E. Quinaux, D. D. Tsao-Wei, W. Eiermann, N. Robert, T. Pienkowski, J. Crown, M. Martin, V. Valero, J. R. Mackey, V. Bee, Y. Ma, I. Villalobos, A. Campeau, M. Mirlacher, M. A. Lindsay and D. J. Slamon (2016). “HER2 Gene Amplification Testing by Fluorescent In Situ Hybridization (FISH): Comparison of the ASCO-College of American Pathologists Guidelines With FISH Scores Used for Enrollment in Breast Cancer International Research Group Clinical Trials.” J Clin Oncol 34(29): 3518-3528.
09-03 Pulford, D. J., P. Harter, A. Floquet, C. Barrett, D. H. Suh, M. Friedlander, J. A. Arranz, K. Hasegawa, H. Tada, P. Vuylsteke, M. R. Mirza, N. Donadello, G. Scambia, T. Johnson, C. Cox, J. K. Chan, M. Imhof, T. J. Herzog, P. Calvert, P. Wimberger, D. Berton-Rigaud, M. C. Lim, G. Elser, C. F. Xu and A. du Bois (2016). “Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study.” BMC Med Ethics 17(1): 63.
14-13 Reck, M., D. Rodriguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer and K.-. Investigators (2016). “Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.” N Engl J Med 375(19): 1823-1833.
06-02 Regan, M. M., P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, G. Viale, M. Colleoni, I. Lang, H. L. Gomez, C. Tondini, G. Pinotti, K. N. Price, A. S. Coates, A. Goldhirsch and R. D. Gelber (2016). “Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.” J Clin Oncol 34(19): 2221-2231.
Scott, K., P. J. Hayden, A. Will, K. Wheatley and I. Coyne (2016). “Bortezomib for the treatment of multiple myeloma.” Cochrane Database Syst Rev 4: CD010816.
10-05 Toomey, S., A. J. Eustace, L. B. Pritzker, K. P. Pritzker, J. Fay, A. O’Grady, R. Cummins, L. Grogan, J. Kennedy, D. O’Connor, L. Young, E. W. Kay, N. O’Donovan, W. M. Gallagher, R. Kalachand, J. Crown and B. T. Hennessy (2016). “RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” J Natl Cancer Inst 108(8).

2015 Publications

Study Number Publication Details
09-01 Finn, R. S., J. P. Crown, I. Lang, K. Boer, I. M. Bondarenko, S. O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. Shparyk, A. R. Thummala, N. L. Voytko, C. Fowst, X. Huang, S. T. Kim, S. Randolph and D. J. Slamon (2015). “The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.” Lancet Oncol 16(1): 25-35.


Floquet, A., I. Vergote, N. Colombo, B. Fiane, B. J. Monk, A. Reinthaller, P. Calvert, T. J. Herzog, W. Meier, J. W. Kim, J. M. del Campo, M. Friedlander, C. Pisano, S. Isonishi, R. J. Crescenzo, C. Barrett, K. Wang, I. Mitrica and A. du Bois (2015). “Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.” Gynecol Oncol 136(1): 37-42.
08-09 Howlin, C., E. O’Shea, M. Dunne, L. Mullaney, M. McGarry, A. Clayton-Lea, M. Finn, P. Carter, B. Garret and P. Thirion (2015). “A randomized controlled trial comparing customized versus standard headrests for head and neck radiotherapy immobilization in terms of set-up errors, patient comfort and staff satisfaction (ICORG 08-09).” Radiography 21(1): 74-83.
08-10 Sparano, J. A., R. J. Gray, D. F. Makower, K. I. Pritchard, K. S. Albain, D. F. Hayes, C. E. Geyer, Jr., E. C. Dees, E. A. Perez, J. A. Olson, Jr., J. Zujewski, T. Lively, S. S. Badve, T. J. Saphner, L. I. Wagner, T. J. Whelan, M. J. Ellis, S. Paik, W. C. Wood, P. Ravdin, M. M. Keane, H. L. Gomez Moreno, P. S. Reddy, T. F. Goggins, I. A. Mayer, A. M. Brufsky, D. L. Toppmeyer, V. G. Kaklamani, J. N. Atkins, J. L. Berenberg and G. W. Sledge (2015). “Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.” N Engl J Med 373(21): 2005-2014.
06-15 Tonry, C. L., D. Doherty, C. O’Shea, B. Morrissey, L. Staunton, B. Flatley, A. Shannon, J. Armstrong and S. R. Pennington (2015). “Discovery and Longitudinal Evaluation of Candidate Protein Biomarkers for Disease Recurrence in Prostate Cancer.” J Proteome Res 14(7): 2769-2783.

2014 Publications

Study Number Publication Details
97-01 Barry, A. S., M. T. Dunne, C. A. Lyons, M. A. Finn, B. Moulton, J. C. Taylor, C. M. O’Shea, P. G. Thirion and J. G. Armstrong (2014). “Temporal patterns of late bowel and bladder radiotherapy toxicity in a randomised controlled trial assessing duration of neo-adjuvant hormones in prostate cancer.” Acta Oncol 53(10): 1390-1397.


Cuzick, J., I. Sestak, J. F. Forbes, M. Dowsett, J. Knox, S. Cawthorn, C. Saunders, N. Roche, R. E. Mansel, G. von Minckwitz, B. Bonanni, T. Palva, A. Howell and I.-I. investigators (2014). “Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.” Lancet 383(9922): 1041-1048.
05-04 Mullaney, L. M., E. O’Shea, M. T. Dunne, M. A. Finn, P. G. Thirion, L. A. Cleary, M. McGarry, L. O’Neill and J. G. Armstrong (2014). “A randomized trial comparing bladder volume consistency during fractionated prostate radiation therapy.” Pract Radiat Oncol 4(5): e203-212.

2013 Publications

Study Number Publication Details
08-20 Araujo, J. C., G. C. Trudel, F. Saad, A. J. Armstrong, E. Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, S. V. Serrano, V. B. Matveev, E. Efstathiou, S. Oudard, M. J. Morris, B. Sizer, P. J. Goebell, A. Heidenreich, J. S. de Bono, S. Begbie, J. H. Hong, E. Richardet, E. Gallardo, P. Paliwal, S. Durham, S. Cheng and C. J. Logothetis (2013). “Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.” Lancet Oncol 14(13): 1307-1316.


Au, H. J., W. Eiermann, N. J. Robert, T. Pienkowski, J. Crown, M. Martin, M. Pawlicki, A. Chan, J. Mackey, J. Glaspy, T. Pinter, M. C. Liu, T. Fornander, S. Sehdev, J. M. Ferrero, V. Bee, M. J. Santana, D. P. Miller, D. Lalla, D. J. Slamon and B. T. I. Translational Research in Oncology (2013). “Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study.” Oncologist 18(7): 812-818.
05-10 Busacca, S., A. D. Chacko, A. Klabatsa, K. Arthur, M. Sheaff, D. Barbone, L. Mutti, V. K. Gunasekharan, J. J. Gorski, M. El-Tanani, V. C. Broaddus, G. Gaudino and D. A. Fennell (2013). “BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.” PLoS One 8(6): e65489.
06-04 Crown, J., M. J. Kennedy, P. Tresca, M. Marty, M. Espie, H. A. Burris, M. DeSilvio, M. R. Lau, D. Kothari, K. M. Koch and V. Dieras (2013). “Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer.” Ann Oncol 24(8): 2005-2011.
07-08 Crown, J. P., V. Dieras, E. Staroslawska, D. A. Yardley, T. Bachelot, N. Davidson, H. Wildiers, P. A. Fasching, O. Capitain, M. Ramos, R. Greil, F. Cognetti, G. Fountzilas, M. Blasinska-Morawiec, C. Liedtke, R. Kreienberg, W. H. Miller, Jr., V. Tassell, X. Huang, J. Paolini, K. A. Kern and G. Romieu (2013). “Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer.” J Clin Oncol 31(23): 2870-2878.
06-14 Kellokumpu-Lehtinen, P. L., U. Harmenberg, T. Joensuu, R. McDermott, P. Hervonen, C. Ginman, M. Luukkaa, P. Nyandoto, A. Hemminki, S. Nilsson, J. McCaffrey, R. Asola, T. Turpeenniemi-Hujanen, F. Laestadius, T. Tasmuth, K. Sandberg, M. Keane, I. Lehtinen, T. Luukkaala, H. Joensuu and P. s. group (2013). “2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.” Lancet Oncol 14(2): 117-124.
98-01 Loi, S., N. Sirtaine, F. Piette, R. Salgado, G. Viale, F. Van Eenoo, G. Rouas, P. Francis, J. P. Crown, E. Hitre, E. de Azambuja, E. Quinaux, A. Di Leo, S. Michiels, M. J. Piccart and C. Sotiriou (2013). “Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.” J Clin Oncol 31(7): 860-867.
06-15 Morrissey, B., C. O’Shea, J. Armstrong, C. Rooney, L. Staunton, M. Sheehan, A. M. Shannon and S. R. Pennington (2013). “Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.” Proteomics Clin Appl 7(5-6): 316-326.
97-01 Mydin, A. R., M. T. Dunne, M. A. Finn and J. G. Armstrong (2013). “Early salvage hormonal therapy for biochemical failure improved survival in prostate cancer patients after neoadjuvant hormonal therapy plus radiation therapy–a secondary analysis of irish clinical oncology research group 97-01.” Int J Radiat Oncol Biol Phys 85(1): 101-108.
98-01 Oakman, C., P. A. Francis, J. Crown, E. Quinaux, M. Buyse, E. De Azambuja, M. Margeli Vila, M. Andersson, B. Nordenskjold, R. Jakesz, B. Thurlimann, J. Gutierrez, V. Harvey, L. Punzalan, P. Dell’orto, D. Larsimont, I. Steinberg, R. D. Gelber, M. Piccart-Gebhart, G. Viale and A. Di Leo (2013). “Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer–8-year results of the Breast International Group 02-98 phase III trial.” Ann Oncol 24(5): 1203-1211.
05-02 Pogue-Geile, K., G. Yothers, Y. Taniyama, N. Tanaka, P. Gavin, L. Colangelo, N. Blackmon, C. Lipchik, S. R. Kim, S. Sharif, C. Allegra, N. Petrelli, M. J. O’Connell, N. Wolmark and S. Paik (2013). “Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.” J Natl Cancer Inst 105(13): 989-992.
 10-18 Shaw, A. T., D. W. Kim, K. Nakagawa, T. Seto, L. Crino, M. J. Ahn, T. De Pas, B. Besse, B. J. Solomon, F. Blackhall, Y. L. Wu, M. Thomas, K. J. O’Byrne, D. Moro-Sibilot, D. R. Camidge, T. Mok, V. Hirsh, G. J. Riely, S. Iyer, V. Tassell, A. Polli, K. D. Wilner and P. A. Janne (2013). “Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.” N Engl J Med 368(25): 2385-2394.
05-11 Swain, S. M., G. Tang, C. E. Geyer, Jr., P. Rastogi, J. N. Atkins, P. P. Donnellan, L. Fehrenbacher, C. A. Azar, A. Robidoux, J. A. Polikoff, A. M. Brufsky, D. D. Biggs, E. A. Levine, J. L. Zapas, L. Provencher, D. W. Northfelt, S. Paik, J. P. Costantino, E. P. Mamounas and N. Wolmark (2013). “Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.” J Clin Oncol 31(26): 3197-3204.

2012 Publications

Study Number Publication Details
06-22 Browne, B. C., A. J. Eustace, S. Kennedy, N. A. O’Brien, K. Pedersen, M. S. McDermott, A. Larkin, J. Ballot, T. Mahgoub, F. Sclafani, S. Madden, J. Kennedy, M. J. Duffy, J. Crown and N. O’Donovan (2012). “Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.” Breast Cancer Res Treat 136(3): 717-727.
08-08 Corcoran, C., S. Rani, K. O’Brien, A. O’Neill, M. Prencipe, R. Sheikh, G. Webb, R. McDermott, W. Watson, J. Crown and L. O’Driscoll (2012). “Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.” PLoS One 7(12): e50999.
97-01 Daly, P. E., M. T. Dunne, C. M. O’Shea, M. A. Finn and J. G. Armstrong (2012). “The effect of short term neo-adjuvant androgen deprivation on erectile function in patients treated with external beam radiotherapy for localised prostate cancer: an analysis of the 4- versus 8-month randomised trial (Irish Clinical Oncology Research Group 97-01).” Radiother Oncol 104(1): 96-102.
07-12 Dowling, P., C. Clarke, K. Hennessy, B. Torralbo-Lopez, J. Ballot, J. Crown, I. Kiernan, K. J. O’Byrne, M. J. Kennedy, V. Lynch and M. Clynes (2012). “Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer.” Int J Cancer 131(4): 911-923.
05-10 Fennell, D. A., C. McDowell, S. Busacca, G. Webb, B. Moulton, A. Cakana, K. J. O’Byrne, J. V. Meerbeeck, P. Donnellan, J. McCaffrey and P. Baas (2012). “Phase II clinical trial of first or second-line treatment with bortezomib in patients with malignant pleural mesothelioma.” J Thorac Oncol 7(9): 1466-1470.
08-21 Fizazi, K., H. I. Scher, A. Molina, C. J. Logothetis, K. N. Chi, R. J. Jones, J. N. Staffurth, S. North, N. J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O. B. Goodman, Jr., C. N. Sternberg, J. H. Li, T. Kheoh, C. M. Haqq, J. S. de Bono and C.-A.-. Investigators (2012). “Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.” Lancet Oncol 13(10): 983-992.

2011 Publications

Study Number Publication Details
06-07 Adams, R. A., A. M. Meade, M. T. Seymour, R. H. Wilson, A. Madi, D. Fisher, S. L. Kenny, E. Kay, E. Hodgkinson, M. Pope, P. Rogers, H. Wasan, S. Falk, S. Gollins, T. Hickish, E. M. Bessell, D. Propper, M. J. Kennedy, R. Kaplan, T. S. Maughan and M. C. T. Investigators (2011). “Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.” Lancet Oncol 12(7): 642-653.


Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, N. J. Petrelli, L. H. Colangelo, J. N. Atkins, T. E. Seay, L. Fehrenbacher, R. M. Goldberg, S. O’Reilly, L. Chu, C. A. Azar, S. Lopa and N. Wolmark (2011). “Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.” J Clin Oncol 29(1): 11-16.
97-01 Armstrong, J. G., C. M. Gillham, M. T. Dunne, D. A. Fitzpatrick, M. A. Finn, M. E. Cannon, J. C. Taylor, C. M. O’Shea, S. J. Buckney and P. G. Thirion (2011). “A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.” Int J Radiat Oncol Biol Phys 81(1): 35-45.
04-01 Coleman, R., E. Woodward, J. Brown, D. Cameron, R. Bell, D. Dodwell, M. Keane, M. Gil, C. Davies, R. Burkinshaw, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee and H. Thorpe (2011). “Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.” Breast Cancer Res Treat 127(2): 429-438.
04-01 Coleman, R. E., H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. Gil, S. J. Houston, R. J. Grieve, P. J. Barrett-Lee, D. Ritchie, J. Pugh, C. Gaunt, U. Rea, J. Peterson, C. Davies, V. Hiley, W. Gregory, R. Bell and A. Investigators (2011). “Breast-cancer adjuvant therapy with zoledronic acid.” N Engl J Med 365(15): 1396-1405.
97-01 D’Amico, A. V., M. H. Chen, J. Crook, J. G. Armstrong, S. Malone, A. Steigler, M. Dunne, P. W. Kantoff and J. W. Denham (2011). “Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.” J Clin Oncol 29(35): 4682-4687.
01-04 Eiermann, W., T. Pienkowski, J. Crown, S. Sadeghi, M. Martin, A. Chan, M. Saleh, S. Sehdev, L. Provencher, V. Semiglazov, M. Press, G. Sauter, M. A. Lindsay, A. Riva, M. Buyse, P. Drevot, H. Taupin and J. R. Mackey (2011). “Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.” J Clin Oncol 29(29): 3877-3884.
97-01 Fleming, C., C. Kelly, P. Thirion, K. Fitzpatrick and J. Armstrong (2011). “A method for the prediction of late organ-at-risk toxicity after radiotherapy of the prostate using equivalent uniform dose.” Int J Radiat Oncol Biol Phys 80(2): 608-613.
06-06 Martin, M., H. Roche, T. Pinter, J. Crown, M. J. Kennedy, L. Provencher, F. Priou, W. Eiermann, E. Adrover, I. Lang, M. Ramos, J. Latreille, A. Jagiello-Gruszfeld, T. Pienkowski, E. Alba, R. Snyder, S. Almel, J. Rolski, M. Munoz, R. Moroose, S. Hurvitz, A. Banos, H. Adewoye, Y. J. Hei, M. A. Lindsay, M. Rupin, D. Cabaribere, Y. Lemmerick, J. R. Mackey and T. investigators (2011). “Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.” Lancet Oncol 12(4): 369-376.
01-03 Slamon, D., W. Eiermann, N. Robert, T. Pienkowski, M. Martin, M. Press, J. Mackey, J. Glaspy, A. Chan, M. Pawlicki, T. Pinter, V. Valero, M. C. Liu, G. Sauter, G. von Minckwitz, F. Visco, V. Bee, M. Buyse, B. Bendahmane, I. Tabah-Fisch, M. A. Lindsay, A. Riva, J. Crown and G. Breast Cancer International Research (2011). “Adjuvant trastuzumab in HER2-positive breast cancer.” N Engl J Med 365(14): 1273-1283.
01-09 Valero, V., J. Forbes, M. D. Pegram, T. Pienkowski, W. Eiermann, G. von Minckwitz, H. Roche, M. Martin, J. Crown, J. R. Mackey, P. Fumoleau, J. Rolski, Z. Mrsic-Krmpotic, A. Jagiello-Gruszfeld, A. Riva, M. Buyse, H. Taupin, G. Sauter, M. F. Press and D. J. Slamon (2011). “Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.” J Clin Oncol 29(2): 149-156.

2010 Publications

Study Number Publication Details
99-09 Brennan, S. M., P. Thirion, S. Buckney, C. O. Shea and J. Armstrong (2010). “Factors influencing conformity index in radiotherapy for non-small cell lung cancer.” Med Dosim 35(1): 38-42.
04-01 Coleman, R. E., M. C. Winter, D. Cameron, R. Bell, D. Dodwell, M. M. Keane, M. Gil, D. Ritchie, J. L. Passos-Coelho, D. Wheatley, R. Burkinshaw, S. J. Marshall, H. Thorpe and A. Investigators (2010). “The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.” Br J Cancer 102(7): 1099-1105.
97-02 Mansi, J. L., A. Yellowlees, J. Lipscombe, H. M. Earl, D. A. Cameron, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, J. Crown, A. L. Jones, M. Highley, R. C. Leonard and T. R. Evans (2010). “Five-year outcome for women randomised in a phase III trial comparing doxorubicin and cyclophosphamide with doxorubicin and docetaxel as primary medical therapy in early breast cancer: an Anglo-Celtic Cooperative Oncology Group study.” Breast Cancer Res Treat 122(3): 787-794.

2009 Publications

Study Number Publication Details
05-02 Allegra, C. J., G. Yothers, M. J. O’Connell, S. Sharif, L. H. Colangelo, S. H. Lopa, N. J. Petrelli, R. M. Goldberg, J. N. Atkins, T. E. Seay, L. Fehrenbacher, S. O’Reilly, L. Chu, C. A. Azar and N. Wolmark (2009). “Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.” J Clin Oncol 27(20): 3385-3390.
04-09 Johnston, S., J. Pippen, Jr., X. Pivot, M. Lichinitser, S. Sadeghi, V. Dieras, H. L. Gomez, G. Romieu, A. Manikhas, M. J. Kennedy, M. F. Press, J. Maltzman, A. Florance, L. O’Rourke, C. Oliva, S. Stein and M. Pegram (2009). “Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.” J Clin Oncol 27(33): 5538-5546.

2008 Publications

Study Number Publication Details
04-08 Cameron, D., M. Casey, M. Press, D. Lindquist, T. Pienkowski, C. G. Romieu, S. Chan, A. Jagiello-Gruszfeld, B. Kaufman, J. Crown, A. Chan, M. Campone, P. Viens, N. Davidson, V. Gorbounova, J. I. Raats, D. Skarlos, B. Newstat, D. Roychowdhury, P. Paoletti, C. Oliva, S. Rubin, S. Stein and C. E. Geyer (2008). “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.” Breast Cancer Res Treat 112(3): 533-543.
98-01 Francis, P., J. Crown, A. Di Leo, M. Buyse, A. Balil, M. Andersson, B. Nordenskjold, I. Lang, R. Jakesz, D. Vorobiof, J. Gutierrez, G. van Hazel, S. Dolci, S. Jamin, B. Bendahmane, R. D. Gelber, A. Goldhirsch, M. Castiglione-Gertsch, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.” J Natl Cancer Inst 100(2): 121-133.
98-01 Pestalozzi, B. C., P. Francis, E. Quinaux, S. Dolci, E. Azambuja, R. D. Gelber, G. Viale, A. Balil, M. Andersson, B. Nordenskjold, M. Gnant, J. Gutierrez, I. Lang, J. P. Crown, M. Piccart-Gebhart and B. I. G. C. Group (2008). “Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial.” Ann Oncol 19(11): 1837-1841.

2007 Publications

Study Number Publication Details
06-03 O’Connor, R., M. O’Leary, J. Ballot, C. D. Collins, P. Kinsella, D. E. Mager, R. D. Arnold, L. O’Driscoll, A. Larkin, S. Kennedy, D. Fennelly, M. Clynes and J. Crown (2007). “A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer.” Cancer Chemother Pharmacol 59(1): 79-87.

2006 Publications

Study Number Publication Details
00-01 Besson, H., P. Brennan, N. Becker, A. Nieters, S. De Sanjose, R. Font, M. Maynadie, L. Foretova, P. L. Cocco, A. Staines, M. Vornanen and P. Boffetta (2006). “Tobacco smoking, alcohol drinking and non-Hodgkin’s lymphoma: A European multicenter case-control study (Epilymph).” Int J Cancer 119(4): 901-908.
04-08 Geyer, C. E., J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron (2006). “Lapatinib plus capecitabine for HER2-positive advanced breast cancer.” N Engl J Med 355(26): 2733-2743.

2004 Publications

Study Number Publication Details
97-02 Leonard, R. C., M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, M. Verrill, D. Cameron, E. Foster, A. Yellowlees, J. Crown and G. Anglo-Celtic Cooperative Oncology (2004). “Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.” J Natl Cancer Inst 96(14): 1076-1083.


2002 Publications

Study Number Publication Details
97-02 Cameron, D. A., A. Anderson, E. Toy, T. R. Evans, J. H. Le Vay, I. C. Kennedy, R. J. Grieve, T. J. Perren, A. Jones, J. Mansi, J. Crown and R. C. Leonard (2002). “Block sequential adriamycin CMF–optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?” Br J Cancer 87(12): 1365-1369.



Selected Presentation Abstracts

2017 Publications

Study Number Publication Details
12-16 Byrne, A. T., D. Smeets, I. S. Miller, S. Das, B. Boeckx, J. Depreeuw, T. Gaiser, J. Betge, A. Barat, V. Murphy, B. Moran, B. Fender, R. Klinger, M. P. Ebert, N. C. T. van Grieken, B. Ylstra, W. M. Gallagher, J. Prehn, D. O’Connor and D. Lambrechts (2017). “Identification of a novel predictive genomic biomarker for response to combination bevacizumab in metastatic colorectal cancer (mCRC).” Poster Presentation– ASCO Annual Meeting. J Clin Oncol 35, 2017 (suppl; abstr 3580).
13-18 Dombret, H., M. S. Topp, A. Schuh, A. Wei, G. Martinelli, S. Durrant, C.L. Bacon, K. Nie, Z. Zimmerman, and H. Kantarjian (2017).“Blinatumomab vs SOC Chemotherapy in First Salvage Compared with Second or Greater Salvage in a Phase 3 Study” Oral Presentation– European Hematology Association. Abstract S478.
09-01 Finn, R. S., J. Crown, I. Lang, K. Boer, I. Bondarenko, S. O. Kulyk, J. Ettl, R. Patel, T. Pinter, M. Schmidt, Y. V. Shparyk, A. Thummala, N. L. Voytko, C. Fowst, X. Huang, S. Kim, D. J. Slamon and D. Geffen (2017). “Overall survival results from the randomized phase II study of palbociclib (P) in combination with letrozole (L) vs letrozole alone for frontline treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18).” Oral Presentation– ASCO Annual Meeting (J Clin Oncol 35, 2017 (suppl; abstr 1001)).
15-43 Kelly, C. M., R. Feighery, J. McCaffrey, M. Higgins, M. Smith, S. O’Reilly, C. Murphy, A. Horgan, J. Walshe, R. McDermott, D. O’Donnell, P.G. Morris, M. Keane, M. Martin, K. Duffy, A. Mihai, J. Armstrong, E. Mulroe, V. Murphy and C. Kelly (2017). “Do Oncology Patients Understand Clinical Trials? A Nationwide Study By Cancer Trials Ireland.” Poster Presentation– ESMO.

2016 Publications

Study Number Publication Details
14-13 Brahmer, J., D. Rodríguez-Abreu, A. Robinson, R. Hui, T. Csőszi, A. Fülöp, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O’Brien, S. Rao, K. Hotta, A. Deitz, G. Lubiniecki, J. Zhang, R. Rangwala and M. Reck (2016). Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS ≥50%: Data from KEYNOTE-024. Oral Presentation– World Conference Lung Cancer 2016 (session PL04A).


Davis, I., M. StockIer, A. J. Martin, W. Hague, X. Coskinas, S. Yip, E. Tu, N. J. Lawrence, H. Chan, R. McDermott, S. Chowdhury, V. Marchesin, O. Deignan, F. Vera-Badillo, S. North, A. Montenegro and S. C. (2016). Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304). Poster Presentation– ASCO; Journal of Clinical Oncology (suppl; abstr TPS5090).
06-32 Mamounas, E., H. Bandos, B. Lembersky, C. Geyer, L. Fehrenbacher, M. Graham, S. Chia, A. Brufsky, B. Hennessy, G. Soori, S. Dakhil, T. Seay, J. Wade, E. McCarron, S. Paik, S. Swain, D. L. Wickerham and N. Wolmark (2016). A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42. Oral Presentation-San Antonio Breast Cancer Symposium.
13-17 O’Gorman, P., M. O’Dwyer, O. Gilligan, J. Quinn, M. Coyne, J. Krawczyk, P. Murphy, L. del Rosario McAlester, O. Harraghy, O. Cormican, E. Lenihan, K. Egan, M. R. Perera, G. Crotty, P. J. Hayden, B. Hennessy, H. O’Leary, K. Scott, I. Parker, M. Cunnane, J. Marron, A. Connell, E. Coghlan, J. Laubach and R. P. (2016). A Phase II Multi-Center Study of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma – Ctrial-IE (ICORG) 13-17 Study. Poster Presentation -American Society of Haematology Annual Meeting and Exposition.

2015 Publications

Study Number Publication Details
08-10 Gullo, G., J. Kennedy, O. Beathnach, J. McCaffrey, M. Keane, M. Martin, R. Gupta, G. Leonard, P. Calvert, P. Donnellan, J. Walshe, E. McDermott, S. Cairney, R. Bose, K. Scott, A. Hernando, I. Parker, D. Tryfonopoulos, B. Moulton and J. Crown (2015). Pilot study of bevacizumab (Bev) in combination with docetaxel (T) and cyclophosphamide (C) as adjuvant treatment (AdjRx) for patients (pts) with early stage (ES) HER-2 normal breast cancer (BrCa) ICORG 08-10. Poster Presentation (#1964)- European Cancer Congress.
07-01 Quinn, F. M., D. Waldron, D. O’Brien, J. Kelly, K. Scott, A. Hayat and E. A. Vandenberghe (2015). Detection of Mutations in SF3B1 in Chronic Lymphocytic Leukaemia Patients By Reverse Transcription (Rt) Polymerase Chain Reaction and High Resolution Melt Curve Analysis, an Alternative Approach to Next Generation Sequencing for Routine Molecular Diagnostic Laboratories? Poster Presentation- American Society of Haematology Annual Meeting and Exposition.
12-24 Stahel, R. A., U. Dafni, O. Gautschi, E. Felip, Curioni-Fontecedro A, S. Peters, B. Massutí, F. Cardenal, A. S.P., M. Früh, M. Pless, S. Popat, A. Kotsakis, S. Cuffe, P. Bidoli, A. Favaretto, E. Carcereny, M. Sanchez Ronco, M. A. Molina and R. Rosell (2015). A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Oral Presentation– European Cancer Congress.
06-36 Wakelee, H. A., S. E. Dahlberg, S. M. Keller, W. J. Tester, D. R. Gandara, S. L. Graziano, A. Adjei, N. Leighl, S. C. Aisner, J. M. Rothman , J. Patel, M. D. Sborov, S. R. McDermott, R. Perez-Soler, A. M. Traynor, C. Butts, T. Evans, L. Horn, S. S. Ramalingam and J. Schiller (2015). Randomized Phase III Trial of Adjuvant Chemotherapy with or without Bevacizumab in Resected Non-Small Cell Lung Cancer (NSCLC): Results of E1505 (ID 1608). Oral Presentation-World Conference on Lung Cancer.